AMT-676 combinations for advanced colorectal cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is an open-label, multi-center phase 2 trial evaluating AMT-676 in combination with 5-fluorouracil, leucovorin, and bevacizumab or cetuximab in patients with unresectable advanced colorectal adenocarcinoma. The study will look at safety, tolerability, and preliminary efficacy, and will also examine how the drug behaves in the body and whether it triggers an immune response. Eligible participants should have measurable disease, good performance status, and adequate organ function, with specific contraception requirements for those of child-bearing potential. Treatment will be administered across three participating hospitals in China. Pharmacokinetics and potential immunogenicity of AMT-676 will be explored alongside clinical outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients must be willing and able to sign the ICF, and to adhere to the study visit schedule and other protocol requirements
* Patients with pathologically confirmed, unresectable advanced colorectal adenocarcinoma
* Patients must have at least one measurable lesion as per RECIST version 1.1
* Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
* Life expectancy ≥6 months
* Patients must have adequate organ function
* Male and female individuals with child bearing potential must agree to take effective contraceptive measures from the moment they sign the informed consent form until 6 months after the last administration of the study drug
* WCBP(Women of Child-Bearing Potential) must have a negative serum pregnancy test within 7 days prior to first dose of the IMP
* Male patients must agree not to donate sperm, and female patients must agree not to donate eggs, while on study treatment and for at least 3 months and 6 months, respectively, after the last dose of the IMP(Investigational Medicinal Product)
* Availability of tumor tissue sample

Exclusion Criteria:

* Prior treatment with any same target
* Systemic anti-neoplastic therapy within five half-lives or 21 days, whichever is shorter, prior to first dose of the IMP
* Persistent toxicities from previous systemic anti-neoplastic treatments of Grade \>1
* Major surgery within 28 days prior to first dose of the IMP, or no recovery from side effects of such intervention, or a surgery is planned to be conducted within the expected participation period of the trial or within 4 weeks after the last administration of the drug
* History of thromboembolic or cerebrovascular events during last 6 mouths
* During the three months prior to the first administration of the drug, there were any life-threatening bleeding events, or grade 3 or higher gastrointestinal/venous variceal bleeding events that required blood transfusion, endoscopy, or surgical treatment. Or there were other diseases that the researchers believed posed a higher risk of bleeding or thrombosis during the study period
* Has a history of interstitial lung disease (ILD)/pneumonitis that required steroids, or current ILD/pneumonitis, or suspected ILD/pneumonitis , or other lung disease significantly impacting lung function at baseline.
* Any other concurrent diseases or conditions that could affect the research judgment or impede the completion of the research procedures and follow-up checks
* Central nervous system (CNS) metastasis
* Have a history of active or acute diverticulitis, abdominal abscess, gastrointestinal obstruction, fistula, or peritoneal cancer
* Any evidence indicates severe or uncontrolled systemic diseases
* Acute and/or clinically significant bacterial, fungal or viral infection including hepatitis B (HBV), hepatitis C (HCV), known human immunodeficiency virus (HIV).
* Administration of a live vaccine within 28 days prior to the administration of the first dose of the IMP
* Patients requiring concurrent treatment of strong/moderate inhibitors or strong inducers of cytochrome P450 3A4 or 1A2 enzyme (CYP3A or CYP1A2) within 2 weeks prior to the first dose and during the study treatment
* Known or suspected severe allergy/hypersensitivity (resulting in treatment discontinuation) to monoclonal antibodies
* Known or suspected intolerance to the components of the IMP
* Concurrent participation in another investigational therapeutic clinical trial
* Pregnant or breast-feeding females
* Investigator determined that the trial participants who were not suitable to participate in this study for other reasons

Where it's running

• Guangxi Medical University Cancer Hospital
  Nanning, Gaungxi, China Recruiting
• Sun Yat-sen University Cancer Center
  Guangzhou, Guangdong, China Recruiting
• Zhujiang Hospital of Southern Medical University
  Guangzhou, Guangdong, China Recruiting
• Shandong Cancer Hospital and Institute
  Jinan, Shandong, China Recruiting
• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting
• Shanghai Tenth People's Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Minqi Guan
• Email: minqi.guan@multitudetherapeutics.com
• Phone: 15895820062

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Petosemtamab plus chemotherapy vs standard chemo plus cetuximab or bevacizumab in RAS/BRAF WT colorectal cancer

  This phase 3 trial tests whether adding petosemtamab to standard chemotherapy works better than the usual chemo plus cetuximab or bevacizumab for people with recurrent, unresectable, or metastatic colorectal cancer that is KRAS/NRAS/BRAF wild type.

  Recruiting at 5 sites Phase 3 Genmab · Hot Springs, Arkansas and 4 other locations · NCT07775287

• Treatment for colorectal cancer patients with liver metastases that can't be surgically removed

  This study is testing two different treatment combinations to see which one helps colorectal cancer patients with liver tumors that can’t be removed by surgery live longer and possibly make their tumors operable.

  Recruiting Phase 3 Fudan University · Shanghai, Shanghai Municipality · NCT04687631

• Neoadjuvant therapy with encorafenib plus cetuximab N01 and mFOLFOX6 in locally advanced BRAF V600E-mutant colorectal cancer

  This trial tests a targeted, pre-surgery treatment to see if it improves the chance of long-term control in adults with locally advanced BRAF V600E-mutant colorectal cancer.

  Recruiting Phase 2 Zhejiang University · Hangzhou, Zhejiang · NCT07789210

• Bevacizumab, sintilimab, cetuximab and irinotecan in refractory RAS wild-type metastatic colorectal cancer

  This trial tests whether adding sintilimab to a cetuximab and irinotecan backbone, with or without bevacizumab, helps patients with heavily pretreated metastatic colorectal cancer that has RAS wild-type tumors.

  Recruiting Phase 2 Guangdong Provincial People's Hospital · Guangzhou, Guangdong · NCT07722754

• IBI363 with Bevacizumab for Advanced Colorectal Cancer

  This phase 3 trial tests whether giving IBI363 with bevacizumab helps patients with advanced colorectal cancer who have not benefited from standard therapies.

  Recruiting at 2 sites Phase 3 Innovent Biologics (Suzhou) Co. Ltd. · Wuhan, Wuhan and 1 other locations · NCT07722494

• TQB2930 plus chemo with or without bevacizumab for HER2-abnormally expressed advanced colorectal cancer

  This trial tests a drug called TQB2930 together with standard chemotherapy, with or without bevacizumab, in adults whose colorectal cancer cannot be removed by surgery and shows HER2 abnormal expression.

  Recruiting at 9 sites Phase 1/2 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Beijing, Beijing Municipality and 30 other locations · NCT07653685

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.